

Special Issue

Advances in Omics Technologies for Precision Medicine in Kidney Diseases

Message from the Guest Editor

Recent advances in omics technologies, such as genomics, proteomics, metabolomics, and transcriptomics, have significantly enhanced our understanding of kidney diseases at a molecular level. These high-throughput techniques provide a comprehensive view of the biological processes involved in kidney pathophysiology, facilitating the identification of novel biomarkers and therapeutic targets. In precision medicine, omics approaches offer personalized insights into disease mechanisms, enabling tailored treatments that improve patient outcomes. This Special Issue aims to highlight cutting-edge research and emerging technologies in the field of omics and their application to precision medicine for kidney diseases. We welcome contributions that explore innovative methodologies, data integration strategies, and the translation of omics findings into clinical practice, ultimately advancing our ability to diagnose, monitor, and treat kidney disorders with a precision medicine approach.

Guest Editor

Prof. Dr. Marijn Speeckaert

Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium

Deadline for manuscript submissions

closed (20 June 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/216418

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).